The role of a lipido-sterolic extract of Serenoa repens in the management of lower urinary tract symptoms associated with benign prostatic hyperplasia.
OBJECTIVE To examine the clinical profile of medication derived from a lipido-sterolic extract of Serenoa repens (saw palmetto) for managing lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). METHODS We reviewed clinical trials involving extracts of S. repens, focusing on the benefit/risk ratio in patients with BPH. RESULTS S. repens extract significantly reduces the symptoms of BPH, increases urinary flow, improves the quality of life and is well tolerated. CONCLUSION Analysis of the overall clinical database indicates that extract of S. repens may be considered a viable first-line therapy for treating LUTS.
Division of Urology, University of Chicago Medical School, Chicago, IL 60637, USA. ggerber@bsd.uchicago.edu
Glenn S
GS
Gerber
John M
JM
Fitzpatrick
D000465:Algorithms; D000726:Androgen Antagonists / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D015201:Meta-Analysis as Topic; D010349:Patient Compliance; D010936:Plant Extracts / Q000008:administration & dosage*; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000503:physiopathology; D011788:Quality of Life; D028024:Serenoa; D016055:Urinary Retention / Q000188:drug therapy*; D014554:Urination / Q000502:physiology
D000726:Androgen Antagonists; D010936:Plant Extracts; C040972:saw palmetto extract